A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

NCT03825718 | Completed Early Phase 1

• 1 other identifier: PGC0002
• Study Type: interventional
• Target: 29
• Locations: 1 country
• Sites: 1

Brief Summary

The study is an early, open, single-centered trial.

Conditions

B-cell Acute Lymphoblastic Leukemia

Outcome Measures

Primary Outcomes (3)

• Number of Patients with Dose Limiting Toxicity

  A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the GC007F cells, which is irreversible, or life threatening or hematologic or non-hematologic Grade 3-5

  12 weeks

• Incidence and severity of adverse events

  After GC007F infusion, adverse events will be graded as CTCAE 4.0

  12 weeks

• GC007F persistence

  After GC007F infusion, GC007F CAR copies in peripheral blood. bone marrow and CSF will be measured by qPCR in 12 weeks

  12 weeks

Secondary Outcomes (1)

• Percents of Patients with best response as complete remission and MRD negative complete remission.

  12 weeks

Study Arms (1)

CAR-T treatment group

EXPERIMENTAL

The patients will receive one dose of GC007F. GC007F dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.

Biological: GC007F

Interventions

GC007F BIOLOGICAL

GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.

CAR-T treatment group

Eligibility Criteria

• Age: 2 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Relapsed or refractory paediatric B-cell ALL 1) 2nd or greater bone marrow (BM) relapse or 2) Relapse after remission for the first time in 12 months or 3) The interval between relapse after allogeneic hematopoietic stem cell transplantation and CAR-T cells transfusion≥100 days or 4) Primary refractory as defined by not achieving a CR after 2 cycles of a standard chemotherapy regimen or chemorefractory as defined by not achieving a CR after 1 cycle of standard chemotherapy for relapsed leukaemia or 5) Patients with Philadelphia chromosome positive ALL were eligible if they were intolerant to or had failed two lines of tyrosine kinase inhibitor (TKI) therapy, or if TKI therapy was contraindicated or 6) Ineligible for allogeneic SCT because of: i. Comorbid disease ii. Other contraindications to allogeneic SCT conditioning regimen iii. Lack of suitable donor iv. Prior SCT v. Declined allogeneic SCT as a therapeutic option after documented discussion, including expected outcomes, about the role of SCT with a BM transplantation physician not part of the study team
• For relapsed patients, CD19 tumour expression demonstrated in bone marrow or peripheral blood by flow cytometry within 3 months of study entry
• Aged 2-70 years
• Eastern cooperative oncology group (ECOG) performance status of 0 to 2
• Life expectancy≥12 weeks
• Adequate organ function defined as:1) Creatinine clearance (as estimated by Cockcroft Gault) \>60 mL/min. 2) Serum ALT/AST\<2.5 ULN. 3) Total bilirubin\<1.5 mg/dl, except in subjects with Gilbert's syndrome. 4) Cardiac ejection fraction≥45%, no evidence of pericardial effusion as determined by an ECHO, and no clinically significant ECG findings. 5) No clinically significant pleural effusion. 6) Baseline oxygen saturation \>92% on room air. 7) pulmonary function: ventilation function is normal or is restricted mildly.
• Females of reproductive age must be in non-lactation period. Females of childbearing potential must have a negative serum or urine pregnancy test. All subjects must use medical-approved-contraception (such as intrauterine device and contraceptive drugs) during the period of trial and in 6 months after cell transfusion therapy.
• The subject agree to and sign informed consent form, willing and able to comply with the planned visit, research, treatment planning, laboratory and other test procedures.

You may not qualify if:

• Isolated extra-medullary disease relapse;
• Patients with Burkitt's lymphoma/leukaemia;
• Central nervous system leukemia involved CNS3;
• Concomitant malignancy other than non-melanoma skin cancer or adequately-treated cervical carcinoma in situ or prostate cancer (PSA score\<1.0) or adequately-treated low grade bladder cancer or surgery-cured ductal carcinoma in situ or diagnosis of other malignancy exceeds 5 years without relapse or treatment during the 5 years;
• Concomitant genetic diseases except Down syndrome;
• Any result of the following virology tests is positive: HIV; HCV; HBsAg; or HBCAb positive with HBV DNA copies positive(≥ 5×10\^2 copies/ml); RPR+TPPA postive;
• Live vaccine ≤4 weeks prior to apheresis;
• Prior CD19 targeted therapy with the exception of subjects who received GC007F in this study and are eligible for re-treatment; Prior chimeric antigen receptor therapy or other genetically modified T cell therapy;
• Presence of grade 2 to 4 graft-versus-host disease (GVHD) after allo-HSCT;
• The following medications were excluded: 1) Steroids: Therapeutic systemic doses of steroids must be stopped \>72 hours prior to tisagenlecleucel infusion. However, the following physiological replacement doses of steroids are allowed: \<12 mg/m\^2/day hydrocortisone or equivalent; 2) Allogeneic cellular therapy: Any donor lymphocyte infusions must be completed \>6 weeks prior to cell infusion; 3) GVHD therapies: Any systemic drug used for GVHD must be stopped \>4 weeks prior to infusion to confirm that GVHD recurrence is not observed;
• Prior treatments of CNS diseases must be stoped \>3 days prior to infusion (e.g., intrathecal injection of methotrexate) 1) Radiotherapy of non-CNS nidus must be completed \>2 weeks prior to infusion; 2) CNS stereotactic radiotherapy must be completed \>8 weeks prior to infusion;
• ≥2 grade toxicities related to previous therapy are not relieved, with the exception of adverse events without safety risk (e.g., alopecia);
• Known life-threatening allergy, hypersensitivity or intolerance to GC007F cells and adjuvant, including DMSO (see investigator's brochure);
• Concomitant disease that may or severe medical condition that may affect patients' safety, including active viral or bacterial infection, uncontrollable systemic fungal infection, uncontrollable cardiac disease, hypertension, abuse of psychoactive drugs, et al.
• Any other condition that may increase subjects' risk or interfere with trial's results.

Sponsors & Collaborators

• Hebei Yanda Ludaopei Hospital: lead
• Gracell Biotechnology Ltd.: collaborator

Study Sites (1)

Hebei Yanda Ludaopei Hospital

Sanhe, Hebei, 065200, China

Location

MeSH Terms

Conditions

Burkitt Lymphoma

Condition Hierarchy (Ancestors)

Epstein-Barr Virus Infections; Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections; Tumor Virus Infections; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Peihua Lu, MD/PHD

  HeiBei YanDa Ludaopei hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 22, 2019
• First Posted: January 31, 2019
• Study Start: January 17, 2019
• Primary Completion: September 1, 2020
• Study Completion: December 1, 2020
• Last Updated: April 28, 2022

Record last verified: 2019-01

Locations

CN (1)